Home News Insights Trading halts Paper trading Guide Community My account

Market calendarNext market opening

Display in USD

Loading news article.

U.S. stock guide
Scanner guide
Paper trading guide
Terms of service
Privacy policy
Announcements
FAQ

Support: help@wapeb.comPartnerships: partnership@wapeb.com

WAPE is a free research, analysis and paper trading service. It does not place real securities orders. Market data and AI summaries are for information only, not investment advice or stock recommendations. Information may include delays, errors or estimates. Check original sources and supporting materials. You are responsible for your investment decisions and any resulting gains or losses.

Language한국어 English

Loading news article.

Cumberland Pharmaceuticals Announces Plans to Submit New Drug Application for Ifetroban in DMD Cardiomyopathy | WAPE

Back All news

Newsfiscal.ai

Cumberland Pharmaceuticals Announces Plans to Submit New Drug Application for Ifetroban in DMD Cardiomyopathy

Oct 27, 2026, 09:05 ET · Published

View source

Article summary

Cumberland Pharmaceuticals plans to submit a New Drug Application (NDA) to the FDA for ifetroban, a potential treatment for cardiomyopathy associated with Duchenne muscular dystrophy (DMD), following a successful pre-NDA meeting.

An excerpt from the original article.

Related companies

Cumberland Pharmaceuticals Inc. Common StockCPIXView stock

Cumberland Pharmaceuticals Announces Plans to Submit New Drug Application for Ifetroban in DMD Cardiomyopathy

Article summary

Related companies

Analyzed by WAPE AI.

Comments —